Table 2.
Prognostic survival analysis according to high or low expression of DCTN family genes
| Gene | Patients (n=438) | No. of events (%) | MST (days) | Crude HR (95% CI) | Crude P-value | Adjusted HRa(95% CI) | Adjusted P valuea |
|---|---|---|---|---|---|---|---|
|
| |||||||
| DCTN1 | 0.131 | 0.446 | |||||
| Low | 219 | 43 (19.6) | 3,042 | Ref. | Ref. | ||
| High | 219 | 55 (25.1) | 2,134 | 0.734 (0.492–1.096) | 0.851 (0.563–1.288) | ||
| DCTN2 | 0.231 | 0.340 | |||||
| Low | 219 | 56 (25.6) | 2,475 | Ref. | Ref. | ||
| High | 219 | 42 (19.2) | N/A | 0.783 (0.525–1.169) | 1.222 (0.810–1.844) | ||
| DCTN3 | 0.649 | 0.594 | |||||
| Low | 219 | 49 (22.4) | 2,821 | Ref. | Ref. | ||
| High | 219 | 49 (22.4) | 2,475 | 1.097 (0.737–1.632) | 1.118 (0.741–1.686) | ||
| DCTN4 | 0.009 | 0.042 | |||||
| Low | 219 | 61 (25.1) | 1,910 | Ref. | Ref. | ||
| High | 219 | 37 (51.5) | N/A | 0.581 (0.386–0.874) | 0.650 (0.429–0.985) | ||
| DCTN5 | 0.958 | 0.701 | |||||
| Low | 219 | 51 (23.3) | 3,042 | Ref. | Ref. | ||
| High | 219 | 47 (21.5) | 2,532 | 1.011 (0.677–1.508) | 0.922 (0.611–1.393) | ||
| DCTN6 | 0.128 | 0.764 | |||||
| Low | 219 | 54 (24.7) | 1,910 | Ref. | Ref. | ||
| High | 219 | 44 (20.1) | 2,821 | 0.733 (0.492–1.093) | 0.938 (0.618–1.424) | ||
Notes:
a
Adjusted for tumor stage. Bold figures indicate statistically significance.
Abbreviations: DCTN, dynactin; MST, median survival time.